• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

User Fee Collections

Back to Table of Contents:  FY 2009 ADUFA Financial Report

ADUFA specifies that the user fees shall be collected for certain animal drug applications and supplements upon their submission, and annual fees shall be collected for certain products, establishments, and sponsors.  The statute also specifies the amount FDA is allowed to collect for each of these categories, and how the fee rates should be adjusted in each fiscal year for increases in workload.

Under ADUFA, fees collected and appropriated, but not spent by the end of a fiscal year, continue to remain available for FDA to spend in future fiscal years.  The balances carried forward from year to year are described on page 7.

The following table provides a breakout of user fees collected by fee category during the past 2 fiscal years, and also reflects the amount of open receivables. 

FOOD AND DRUG ADMINISTRATION
STATEMENT OF ANIMAL DRUG USER FEE COLLECTIONS
AND RECEIVABLES BY FEE SOURCES
AS OF SEPTEMBER 30, 2009

Fees CollectedFY 2008FY 2009
Application Fees$1,983,750$2,339,850
Product Fees$3,262,630$3,787,325
Establishment Fees$3,179,810$3,461,253
Sponsor Fees$3,116,844$3,316,008
TOTAL COLLECTIONS$11,543,034$12,904,435

 

Fees ReceivableFY 2008FY 2009
Product Fees$4,370$14,775
Establishment Fees$52,700$46,297
Sponsor Fees$175,600$531,048
TOTAL RECEIVABLES$232,670$592,120

 


User fee collections are reported in the year the fee was originally due—referred to as cohort years.  For example, a fee originally due in FY 2008, even if it is received in FY 2009, is attributed to FY 2008 collections.  In FY 2009, FDA received a net of $365,434 that was attributed to FY 2008 collections.  Therefore, FDA increased its FY 2008 fee collections of $11,177,600 reported last year to $11,543,034 as of September 30, 2009. 

The receivables for FY 2008 and FY 2009 are from uncollected product, establishment, and sponsor fees.  After 90 days of trying to collect the delinquent debt, FDA turns these receivables over to the Program Support Center (PSC) of the Office of the Secretary for further attempts at collection.  After 180 days of the debt being outstanding, PSC will turn the debt over to the United States Treasury for further collection efforts.

Totals reported for each fiscal year are net of any refunds for that year.  In order to ensure the quality of the information provided in this financial report, FDA updates prior year collections and receivables each year.
 

Next Section:  Obligation of User Fee Obligations